413 related articles for article (PubMed ID: 19722103)
21. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
Cairoli E; Eller-Vainicher C; Ulivieri FM; Zhukouskaya VV; Palmieri S; Morelli V; Beck-Peccoz P; Chiodini I
Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095
[TBL] [Abstract][Full Text] [Related]
22. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Ettinger MP
Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
[TBL] [Abstract][Full Text] [Related]
23. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
Cadarette SM; Katz JN; Brookhart MA; Stürmer T; Stedman MR; Solomon DH
Ann Intern Med; 2008 May; 148(9):637-46. PubMed ID: 18458276
[TBL] [Abstract][Full Text] [Related]
24. Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
Everts-Graber J; Bonel H; Lehmann D; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
Osteoporos Int; 2023 Nov; 34(11):1961-1973. PubMed ID: 37493978
[TBL] [Abstract][Full Text] [Related]
25. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Albert SG; Reddy S
Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
[TBL] [Abstract][Full Text] [Related]
26. Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women.
Osaki M; Tatsuki K; Hashikawa T; Norimatsu T; Chiba K; Motokawa S; Furuichi I; Doiguchi Y; Aoyagi K; Shindo H
Osteoporos Int; 2012 Feb; 23(2):695-703. PubMed ID: 21394496
[TBL] [Abstract][Full Text] [Related]
27. [Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].
Netelenbos JC
Ned Tijdschr Geneeskd; 2001 Jul; 145(28):1336-8. PubMed ID: 11484428
[TBL] [Abstract][Full Text] [Related]
28. Ibandronate in the Prevention of Vertebral and Nonvertebral Osteoporotic Fractures: A Systematic Review of Experimental and Observational Studies.
Mendes D; Penedones A; Alves C; Oliveira T; Donato A; Batel-Marques F
J Clin Rheumatol; 2023 Mar; 29(2):78-83. PubMed ID: 36731043
[TBL] [Abstract][Full Text] [Related]
29. Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods.
Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
J Endocrinol Invest; 2014 Aug; 37(8):769-773. PubMed ID: 25008458
[TBL] [Abstract][Full Text] [Related]
30. Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.
Chapurlat RD
Treat Endocrinol; 2005; 4(2):115-25. PubMed ID: 15783248
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
[TBL] [Abstract][Full Text] [Related]
32. Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials.
Deardorff WJ; Cenzer I; Nguyen B; Lee SJ
JAMA Intern Med; 2022 Jan; 182(1):33-41. PubMed ID: 34807231
[TBL] [Abstract][Full Text] [Related]
33. Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
Katayama K; Matsuno T
Clin Drug Investig; 2008; 28(3):149-58. PubMed ID: 18266400
[TBL] [Abstract][Full Text] [Related]
34. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database.
Watts NB; Worley K; Solis A; Doyle J; Sheer R
J Manag Care Pharm; 2004; 10(2):142-51. PubMed ID: 15032563
[TBL] [Abstract][Full Text] [Related]
35. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
Davis S; Martyn-St James M; Sanderson J; Stevens J; Goka E; Rawdin A; Sadler S; Wong R; Campbell F; Stevenson M; Strong M; Selby P; Gittoes N
Health Technol Assess; 2016 Oct; 20(78):1-406. PubMed ID: 27801641
[TBL] [Abstract][Full Text] [Related]
36. Bisphosphonates for Secondary Prevention of Osteoporotic Fractures: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Shi L; Min N; Wang F; Xue QY
Biomed Res Int; 2019; 2019():2594149. PubMed ID: 31828096
[TBL] [Abstract][Full Text] [Related]
37. Risedronate prevents hip fractures, but who should get therapy?
Deal CL
Cleve Clin J Med; 2002 Dec; 69(12):964, 968-70, 973-6. PubMed ID: 12546269
[TBL] [Abstract][Full Text] [Related]
38. Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study.
Ferrari S; Nakamura T; Hagino H; Fujiwara S; Lange JL; Watts NB
J Bone Miner Metab; 2011 Sep; 29(5):561-70. PubMed ID: 21225297
[TBL] [Abstract][Full Text] [Related]
39. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
Ringe JD; Möller G
Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
[TBL] [Abstract][Full Text] [Related]
40. Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women.
Ellis AG; Reginster JY; Luo X; Bushmakin AG; Williams R; Sutradhar S; Mirkin S; Jansen JP
Curr Med Res Opin; 2014 Aug; 30(8):1617-26. PubMed ID: 24773456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
